AVAC, Health GAP and the Treatment Action Group (TAG) strongly condemn the Trump Administration’s withdrawal from the World Health Organization (WHO).
Treatment Action Group welcomes the Global Drug Facility / Stop TB Partnership's negotiation of what amounts to a 32% savings on bedaquiline, the backbone of improved, all-oral regimens for treating drug-resistant TB.
Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).
On this podcast, Dr. Madhukar Pai describes the ways that the COVID-19 pandemic has delayed and limited access to TB diagnostic testing, and how all stakeholders must step-up efforts to mitigate these impacts and ensure that TB diagnostic testing is not abandoned in the response to COVID-19.
Treatment Action Group (TAG) welcomes the news that long-acting injectable cabotegravir (CAB LA, from ViiV Healthcare) demonstrated a high level of efficacy for preventing HIV infection in cisgender men and transgender women who have sex with men in the HIV Prevention Trials Network (HPTN) 083 trial.
ICAP at Columbia, TAG, and the COVID-19 Working Group – New York presented this webinar on May 13, 2020.
The COVID-19 pandemic is a global health emergency that may demand new, safe, and expedited ways of conducting ethical research to find the solutions we need, including a safe and effective vaccine.
The English version of this publication updated 2024. Please refer to the earlier versions on this page if you need languages other than English. English version updated April 2020. The updated guide reflects new information from recently completed clinical…
On 24 April 2020, advocates sent an open letter to the Diagnostics Supply Consortium calling for a higher level of global coordination, transparency, and accountability to ensure sustainable and equitable access to molecular diagnostic testing for COVID-19...